Zofran 8 mg Norveška - norveški - Statens legemiddelverk

zofran 8 mg

sandoz a/s - ondansetronhydroklorid - tablett, filmdrasjert - 8 mg

Zofran 4 mg Norveška - norveški - Statens legemiddelverk

zofran 4 mg

sandoz a/s - ondansetronhydroklorid - tablett, filmdrasjert - 4 mg

Zofran 4 mg Norveška - norveški - Statens legemiddelverk

zofran 4 mg

sandoz a/s - ondansetronhydroklorid - smeltetablett - 4 mg

Zofran 8 mg Norveška - norveški - Statens legemiddelverk

zofran 8 mg

sandoz a/s - ondansetronhydroklorid - smeltetablett - 8 mg

Zofran 16 mg Norveška - norveški - Statens legemiddelverk

zofran 16 mg

novartis norge as - ondansetronhydroklorid - stikkpille - 16 mg

Zofran 0.8 mg/ ml Norveška - norveški - Statens legemiddelverk

zofran 0.8 mg/ ml

2care4 aps - ondansetronhydrokloriddihydrat - mikstur, oppløsning - 0.8 mg/ ml

Zofran 16 mg Norveška - norveški - Statens legemiddelverk

zofran 16 mg

orifarm as - ondansetron - stikkpille - 16 mg

Zofran 16 mg Norveška - norveški - Statens legemiddelverk

zofran 16 mg

orifarm as - ondansetron - stikkpille - 16 mg

Zofran 16 mg Norveška - norveški - Statens legemiddelverk

zofran 16 mg

orifarm as - ondansetron - stikkpille - 16 mg

Vanflyta Europska Unija - norveški - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.